Nippon Shinyaku (4516) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Cumulative Q3 results showed higher revenue but lower earnings. While profitability remained at a high level, increased SG&A expenses and a higher tax burden weighed on earnings. Revenue was ¥1,271.3B (+4.8% YoY), Operating Income was ¥323.3B (-1.3% YoY), and Net Income was ¥258.5B (attributable to owners of the parent, -9.5% YoY). The gross margin remained high at 67.0% but declined from the previous year, while SG&A expenses increased at a faster pace than revenue growth, which was the primary cause of the decline in Operating Income. The larger decline in Net Income was mainly attributable to the increase in the effective tax rate.

Factors Affecting Earnings

【Revenue】Revenue was ¥1,271.3B, representing a 4.8% increase YoY. Gross profit increased by ¥26.1B to ¥851.2B (¥825.1B in the previous year), although the gross margin declined by approximately 1pt from the previous year to 67.0%.

【Profit and Loss】SG&A expenses increased 15.9% YoY to ¥317.0B, significantly exceeding the 4.8% revenue growth rate. As a result, Operating Income was ¥323.3B (-1.3% YoY), and the Operating Income margin contracted by 157bp YoY to 25.4%. Profit Before Tax was nearly flat at ¥332.3B (-0.6% YoY), but the effective tax rate increased from approximately 14.6% in the previous year to 22.2%, resulting in a wider decline in Net Income to ¥258.5B (-9.5% YoY). R&D expenses were ¥230.3B (18.1% of revenue, -2.2% YoY), indicating that the primary cause of the deterioration in profitability was the increase in SG&A expenses rather than R&D expenses. Overall, the current period recorded higher revenue but lower earnings.

Key Financial Metrics

【Profitability】The Operating Income margin of 25.4% (27.0% in the previous year) and Net Income margin of 20.3% (23.5% in the previous year) both declined from the previous year, but remained high in absolute terms. Annualized ROE was 12.1%, while the R&D expense ratio was 18.1%, representing a standard level of investment for a pharmaceutical company. 【Cash Flow Quality】Operating Cash Flow (OCF) was ¥120.0B, equivalent to approximately 0.46x Net Income of ¥258.5B. Increases in accounts receivable and inventories are delaying the conversion of earnings into cash. 【Investment Efficiency】Capital expenditures were ¥23.4B and intangible asset acquisitions were ¥7.2B, neither of which was excessive relative to the scale of the business. Free Cash Flow was sufficient to cover dividend payments even when measured on an OCF basis. 【Financial Soundness】With an Equity Ratio of 86.5%, cash and cash equivalents of ¥607.7B, and a debt-to-equity ratio of 0.15x, the company has an extremely conservative financial structure and limited short-term funding constraints.

Cash Flow Analysis

OCF was ¥120.0B, down 29.9% from ¥171.3B in the same period of the previous year. The ¥111.6B increase in accounts receivable and ¥60.4B increase in inventories were the primary sources of cash outflow, while the offsetting effect of the ¥11.6B increase in accounts payable was limited. Investing Cash Flow was an inflow of ¥15.2B, including proceeds from the sale of investment securities and other items; however, operating-basis Free Cash Flow after deducting ¥23.4B in capital expenditures was only ¥96.6B. Financing Cash Flow was an outflow of ¥92.4B, mainly due to dividend payments of ¥80.9B. Cash and cash equivalents reached ¥607.7B, providing sufficient short-term liquidity; however, continued working capital expansion could weigh on future cash-generation capacity.

Earnings Quality

While Profit Before Tax remained nearly at the previous year’s level at ¥332.3B, the increase in the effective tax rate from approximately 14.6% in the previous year to 22.2% widened the decline in Net Income, indicating that changes in the tax burden affected earnings quality. Financial income of ¥10.1B exceeded financial expenses of ¥1.2B and, together with the net contribution of other income of ¥23.0B and other expenses of ¥3.5B, provided a certain degree of support to recurring business earnings. These non-operating items should be evaluated separately because their recurrence differs from the underlying earnings power of the business. The accrual ratio remained below 5%, and there are no significant concerns regarding the quality of accounting earnings itself. However, the low OCF/Net Income ratio of 0.46x indicates a timing lag between accrual-basis earnings and cash generation caused by increases in accounts receivable and inventories.

Earnings Forecasts and Guidance

Progress against the full-year company forecasts was 74.8% for Revenue, 98.0% for Operating Income, and 98.3% for Net Income. Revenue progress was at a standard level after taking seasonality into account, but earnings progress was significantly ahead of schedule. Based on the full-year forecast of Operating Income of ¥330.0B (-6.9% YoY), Q4 Operating Income on a standalone basis would be calculated to be only marginal. The company appears to anticipate a concentration of expenses or a significant decline in the profit margin in Q4, which is consistent with the full-year forecast for Net Income to decline 19.2% YoY.

Shareholder Returns

The interim dividend was ¥62.00 per share, and the cumulative Payout Ratio based on the average number of shares outstanding during the period was 16.9%. The full-year forecast dividend is ¥124.00 per share, implying forecast total dividend payments of approximately ¥83.5B and a forecast Payout Ratio of approximately 31.8% against forecast full-year Net Income of ¥263.0B. No share buybacks were conducted, and the Total Return Ratio is therefore the same as the Payout Ratio. Given the financial foundation of cash and cash equivalents of ¥607.7B and an Equity Ratio of 86.5%, short-term constraints on the current dividend level are limited. However, if the declining trend in the OCF/Net Income ratio continues, the source of future dividend funding will require monitoring.

Risk Factors

1. Deterioration in cash conversion: The OCF/Net Income ratio remained at 0.46x, while accounts receivable increased 26.9% YoY and inventories increased 14.4% YoY. If the situation in which earnings growth is not translating into cash generation continues, there is a risk of further deterioration in OCF.

2. Margin pressure from increased SG&A expenses: SG&A expenses increased 15.9% YoY, significantly exceeding the 4.8% revenue growth rate and reducing the Operating Income margin by 157bp. The key focus going forward will be how this increase translates into revenue growth.

3. Uncertainty regarding Q4 earnings composition: Earnings progress against the full-year forecast has reached approximately 98%. Based on the full-year forecast of a 6.9% YoY decline in Operating Income, a significant decline in the Q4 profit margin may already be embedded. The timing of expense recognition and the presence or absence of temporary factors will be variables in evaluating performance.

Industry Benchmark (Reference, Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

The company’s profitability is substantially above the industry level, maintaining positive earnings and a high profit margin in an industry where the median is negative.

Growth and Capital Efficiency

The company’s revenue growth rate substantially exceeds the industry median, securing relatively stable revenue growth in an industry with many companies experiencing revenue declines.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. A key point in the earnings results is that, despite maintaining high profitability and financial soundness, as reflected in an Operating Income margin of 25.4% and an Equity Ratio of 86.5%, the OCF/Net Income ratio remained at 0.46x, with increases in accounts receivable and inventories delaying the conversion of earnings into cash.

2. Earnings progress against the full-year forecast was high at approximately 98%. Since the full-year forecast itself anticipates lower earnings YoY (Operating Income -6.9%, Net Income -19.2%), the composition of Q4 expenses and revenue will be an important variable in evaluating performance.

3. Whether the company can contain the increase in SG&A expenses while maintaining an R&D expense ratio of 18.1% will be a structural issue determining the future trend in the Operating Income margin.

Theoretical Share Price (Reference Value)

Sensitivity: ¥4,202–¥4,450 at ±1% for the cost of equity, and ¥4,321–¥4,327 at ±0.1 for ω.

Notes:

• Because Net Income progress against the full-year forecast (98%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of schedule tend to exceed their forecasts; adjustments may be excessive for businesses with strong seasonality).
• Net assets as of the end of the quarter were used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, consulting with professionals as necessary.

---End of Report---